Rebetol pediatric approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering-Plough gains approval July 30 for use of its hepatitis C treatment Rebetol (ribavirin) with its Intron A (interferon alfa-2b) in patients aged three years and older. A pediatric study of Rebetol in combination with Schering's pegylated interferon product, PEG-Intron,is planned. Rebetol has orphan status for pediatric hepatitis C treatment. Schering is required to conduct a Phase IV long-term follow-up pediatric study; patients who completed the 24-week study will be evaluated yearly for another five years. Generic ribavirin is expected to enter the market shortly, following FDA resolution of labeling and 180-day exclusivity issues...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.